CN Patent

CN112574200B — Btk和/或btk的突变体c481s的小分子抑制剂

Assigned to Anrun Pharmaceutical Technology Suzhou Co ltd · Expires 2021-06-11 · 5y expired

What this patent protects

本发明涉及一种BTK和/或BTK的突变体C481S的小分子抑制剂，其包括式I所示的化合物或其烯醇化物、立体异构体、互变异构体、水合物、溶剂化物或药学上可接受的盐，上述化合物可用于制备预防和/或治疗BTK的活性异常和/或BTK的突变体C481S的活性异常有关的疾病的药物，如自身免疫性疾病、炎症性疾病或癌症。

USPTO Abstract

本发明涉及一种BTK和/或BTK的突变体C481S的小分子抑制剂，其包括式I所示的化合物或其烯醇化物、立体异构体、互变异构体、水合物、溶剂化物或药学上可接受的盐，上述化合物可用于制备预防和/或治疗BTK的活性异常和/或BTK的突变体C481S的活性异常有关的疾病的药物，如自身免疫性疾病、炎症性疾病或癌症。

Drugs covered by this patent

Patent Metadata

Patent number
CN112574200B
Jurisdiction
CN
Classification
—
Expires
2021-06-11
Drug substance claim
No
Drug product claim
No
Assignee
Anrun Pharmaceutical Technology Suzhou Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.